Skip to Main Content

Author Details

Waldemar Priebe
The University of Texas MD Anderson Cancer Center
1972
191
50
PMIDPaper TitleJournal TitlePublished Year
36926129Collagen matrix scaffolds: Future perspectives for the management of chronic liver diseases.World J Clin Cases2023
37556555Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts.Sci Transl Med2023
36951632Development of a Novel Tool To Demystify Drug Distribution at Tissue-Blood Barriers.Chembiochem2023
36966697Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?Eur J Cancer2023
37356236d-Glucose- and d-mannose-based antimetabolites. Part 4: Facile synthesis of mono- and di-acetates of 2-deoxy-d-glucose prodrugs as potentially useful antimetabolites.Carbohydr Res2023
35233572TARGETED DOWN REGULATION OF CORE MITOCHONDRIAL GENES DURING SARS-COV-2 INFECTION.bioRxiv2022
35575067A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.CNS Oncol2022
35427095Correction: X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-d-glucose in solid state and solution.RSC Adv2022
35424802X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-d-glucose in solid state and solution.RSC Adv2022
36144664The Antiviral Effects of 2-Deoxy-D-glucose (2-DG), a Dual D-Glucose and D-Mannose Mimetic, against SARS-CoV-2 and Other Highly Pathogenic Viruses.Molecules2022
33340032Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers.Nat Metab2021
33918425Experimental and Computational Studies on Structure and Energetic Properties of Halogen Derivatives of 2-Deoxy-D-Glucose.Int J Mol Sci2021
34944565Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model.Biomedicines2021
34578985Plant-Derived and Dietary Hydroxybenzoic Acids-A Comprehensive Study of Structural, Anti-/Pro-Oxidant, Lipophilic, Antimicrobial, and Cytotoxic Activity in MDA-MB-231 and MCF-7 Cell Lines.Nutrients2021
34624208Role of miR-2392 in driving SARS-CoV-2 infection.Cell Rep2021
33948587The Great Deceiver: miR-2392's Hidden Role in Driving SARS-CoV-2 Infection.bioRxiv2021
32340173Drug Conjugates for Targeting Eph Receptors in Glioblastoma.Pharmaceuticals (Basel)2020
33230295An enolase inhibitor for the targeted treatment of ENO1-deleted cancers.Nat Metab2020
32605912Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.Clin Cancer Res2020
31404861Curcumin as tyrosine kinase inhibitor in cancer treatment.Eur J Med Chem2019
33981979Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models.Surg Open Sci2019
319057452-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents.Int J Mol Sci2019
31385757Hyperpolarized Pyruvate MR Spectroscopy Depicts Glycolytic Inhibition in a Mouse Model of Glioma.Radiology2019
29923182Profiles of brain metastases: Prioritization of therapeutic targets.Int J Cancer2018
27923328Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.Tissue Eng Part A2017
28417283Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.Invest New Drugs2017
28825042Novel Molecular Multilevel Targeted Antitumor Agents.Cancer Transl Med2017
26861698Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.J Transl Med2016
27576731IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.J Natl Cancer Inst2016
25689150Autophagy modulates the effects of bis-anthracycline WP631 on p53-deficient prostate cancer cells.J Cell Mol Med2015
26498188Obituary: Derek Horton (1933-2015).Glycoconj J2015
25881542Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells.Oncotarget2015
25966666Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway.Stem Cells2015
23800968Integrative biological analysis for neuropsychopharmacology.Neuropsychopharmacology2014
25465288Therapeutic targets in subependymoma.J Neuroimmunol2014
25282014Apples: content of phenolic compounds vs. variety, part of apple and cultivation model, extraction of phenolic compounds, biological properties.Plant Physiol Biochem2014
25146330Analogs of cinnamic acid benzyl amide as nonclassical inhibitors of activated JAK2 kinase.Curr Cancer Drug Targets2014
24804649Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo.PLoS One2014
23376241D-Glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated D-glucose, D-mannose, and 2-deoxy-D-glucose.Carbohydr Res2013
23523885Development of novel molecular probes of the Rio1 atypical protein kinase.Biochim Biophys Acta2013
23359207Regulation of HGF expression by οEGFR-mediated c-Met activation in glioblastoma cells.Neoplasia2013
21792892The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.Int J Cancer2012
22753228Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma.Neuro Oncol2012
22555804Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells.Cancer Biol Ther2012
22249692Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.J Neurooncol2012
21183952Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.Leukemia2011
21855629A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.Cell Signal2011
21935404Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms.PLoS One2011
21907928An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.Cancer Cell2011
21692052Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.Cancer2011
  • 1 - 50 of 191

Recommended Authors

Faculty of Pharmacy, University of Seville
Career Start Year 2010
Number of shared co-authors 0
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 0
Instituto de Investigaciones Biomedicas "Alberto Sols"
Career Start Year 2001
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute
Career Start Year 2001
Number of shared co-authors 1
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 0
Ontario Institute for Cancer Research, University Avenue
Career Start Year 1999
Number of shared co-authors 0
St. Jude Children's Research Hospital
Career Start Year 1997
Number of shared co-authors 3
University of Illinois at Urbana-Champaign
Career Start Year 1995
Number of shared co-authors 0
Middle East Technical University
Career Start Year 1994
Number of shared co-authors 1
Career Start Year 1992
Number of shared co-authors 1
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 1
National Cancer Institute
Career Start Year 1986
Number of shared co-authors 1
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 0
University of Turin
Career Start Year 1985
Number of shared co-authors 0
Discovery and Preclinical Sciences
Career Start Year 1984
Number of shared co-authors 2
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 0
Greenebaum Comprehensive Cancer Center, University of Maryland
Career Start Year 1979
Number of shared co-authors 0
University of Toronto
Career Start Year 1979
Number of shared co-authors 1
National Cancer Institute
Career Start Year 1978
Number of shared co-authors 1
Mayo Clinic
Career Start Year 1977
Number of shared co-authors 5
University Hospital Munster
Career Start Year 1976
Number of shared co-authors 2
Institute of Biomedical Engineering (IBME), University of Oxford
Career Start Year 1976
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1975
Number of shared co-authors 0
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 4
Moores Cancer Center and Department of Medicine, University of California
Career Start Year 1974
Number of shared co-authors 0
The Institute of Cancer Research
Career Start Year 1974
Number of shared co-authors 5
The University of Texas Health Science Center at San Antonio
Career Start Year 1971
Number of shared co-authors 10
PHusis Therapeutics Inc.
Career Start Year 1970
Number of shared co-authors 10
The University of Texas MD Anderson Cancer Center
Career Start Year 1968
Number of shared co-authors 23
Stanford University School of Medicine
Career Start Year 1968
Number of shared co-authors 1

Collaborators

Northwestern University Feinberg School of Medicine
Co-authored papers 17
The University of Texas MD Anderson Cancer Center
Co-authored papers 15
The University of Texas MD Anderson Cancer Center
Co-authored papers 14
MD Anderson Cancer Center
Co-authored papers 11
The University of Texas M.D. Anderson Cancer Center, American University of Beirut
Co-authored papers 10
South China University of Technology
Co-authored papers 8
Huntsman Cancer Institute, University of Utah
Co-authored papers 6
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 6
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 5
Co-authored papers 4
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Co-authored papers 4
Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Lund University
Co-authored papers 3
Baylor College of Medicine, The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Co-authored papers 3
NYU Grossman School of Medicine
Co-authored papers 3
Co-authored papers 3
American Association for Cancer Research, Henry Ford Hospital, Ludwig Institute for Cancer Research, National Cancer Institute, Salk Institute for Biological Studies, University of Cambridge, University of Texas MD Anderson Cancer Center, Virginia Commonwealth University
Co-authored papers 3
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
National Cancer Institute
Co-authored papers 3
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
University of North Carolina at Chapel Hill.
Co-authored papers 2
Co-authored papers 2
University of Michigan Rogel Cancer Center.
Co-authored papers 2